Eptifibatide

• IM: 20 mg/10 mL (2 mg/mL)
• Premixed infusion bag: 75 mg/100 mL (0.75 mg/mL)

Administration:

• Administer via IV only in a clinical setting with access to monitoring and emergency support.
• IV Bolus: Administer over 1–2 minutes.
• IV Infusion: Use an infusion pump for accuracy. Continue as per ACS or PCI protocol.
• Always adjust dose for renal function.
• Monitor platelet counts, hemoglobin/hematocrit, and signs of bleeding throughout therapy.

Storage:

• Store at 2°C to 8°C (36°F to 46°F)
• Do not freeze. Protect from light.
• Use within 24 hours after opening premixed bag or vial.

• Class: Antiplatelet, GPIIb/IIIa receptor antagonist
• Mechanism: Inhibits final common pathway of platelet aggregation by blocking fibrinogen binding to GPIIb/IIIa on platelets
• Onset: Immediate after IV administration
• Half-life: ~2.5 hours
• Duration: Platelet function returns in 4–8 hours after discontinuation
• Excretion: Primarily renal

Common:

• Bleeding (minor or major)
• Nausea
• Hypotension
• Headache

Serious:

• Intracranial hemorrhage
• Severe thrombocytopenia
• Anaphylaxis (rare)

• Active internal bleeding
• History of hemorrhagic stroke
• Recent stroke (within 30 days)
• Major surgery or trauma within 6 weeks
• Severe hypertension (uncontrolled)
• Thrombocytopenia (<100,000/mm³)
• Renal dialysis
• Hypersensitivity to eptifibatide or its components

• Anticoagulants (e.g., heparin, warfarin): ↑ bleeding risk
• Antiplatelets (e.g., aspirin, clopidogrel): additive bleeding risk
• NSAIDs: may potentiate bleeding
• Avoid concurrent use with other GPIIb/IIIa inhibitors